

13-17 September

# ESMO / 24

*What's in store?*

#1

**New Territories for ICIs  
& Navigating the Quest  
of Further Expansion**

#2

#3

**Peering Ahead:  
The Next Wave of  
ADCs in View**



WHAT'S IN STORE?

ESMO 24  
13-17 September

#1

## New Territories for ICIs & Navigating the Quest of Further Expansion

Immune checkpoint inhibitors (ICIs), particularly anti-PD-(L)1 therapies, have become a cornerstone of cancer immunotherapy, and their influence continues to grow. With new agents striving to find their place and established brands pushing for approvals in earlier stages of disease, the momentum behind ICIs isn't slowing down anytime soon.

ESMO 2024 is set to deliver **data for anti-PD-(L)1 therapies in 'untapped' indications**, like first-line squamous cell carcinoma of the anal canal and perioperative use in muscle-invasive bladder cancer (MIBC). Plus, in high-risk early-stage triple-negative breast cancer (TNBC) and high-risk locally advanced cervical cancer, OS readouts **look to cement and validate** the use of pembrolizumab in these settings.

### Developments on our radar

- The attention and weight being given to the **ongoing debate around perioperative trial design** for ICIs
- Clarity on the proposition of **ICI rechallenge** in renal cell carcinoma following TiNivo-2
- Whether new agents reinvigorate excitement for **ICI combination therapies**



WHAT'S IN STORE?

ESMO 24  
13-17 September

#2

## Charting the Course for Radioligand Therapy in Prostate Cancer

The treatment landscape for advanced prostate cancer has undergone significant transformation in recent years, and PSMA-targeted therapies have been a significant development. But there are still plenty of unanswered questions and practical hurdles that have slowed down their wider use. Right now, there's a surge of research focused on figuring out the **best timing and combinations** for these therapies. The data coming out of ESMO 2024 should provide much-needed clarity on how to integrate and sequence radioligand therapy.

### Developments on our radar

- **Conviction in earlier use:** the initial readout from PSMAfore led to mixed opinions. How is the temperament changing with the latest updates and the results of SPLASH?
- **Combination strategies generating the most excitement:** with so many potential pairings, which combinations are physicians most optimistic about?
- **The evolving role of Radium-223:** what is the role of Ra-223 in the evolving treatment landscape?
- **Infrastructure challenges:** as the potential for PSMA-targeted radioligand therapy grows, how can infrastructure evolve to support more widespread use?





## Peering Ahead: The Next Wave of ADCs in View

Antibody-drug conjugates (ADCs) have been the star of the show in recent years, but as we dive into the ESMO 24 programme, it's clear that the focus is shifting to the next generation of these innovative therapies. This year, **over ten early-phase ADC oral presentations are lined up**, signalling that the spotlight is now on emerging agents. Despite the early-stage nature of the data, plenty of buzz is still expected, given the high-value deals and partnerships forged in the ADC space over the past year.

### Developments on our radar

- **BL-B01D1, a bispecific ADC targeting EGFR and HER3:** bispecific ADCs are one of the exciting ADC formats appearing, offering the potential for enhanced tumor specificity.
- **AZD5335 (FRa targeted ADC):** following preclinical data, there is speculation about whether AZD5335 could become a best-in-class therapy with greater bystander potential.
- **PD-L1 as a target for ADCs:** PD-L1 is a familiar target, but using it as a target for an ADC is a totally different ball game.



## Abstract titles

Abstracts referenced include those most prominently positioned within the programme and are by no means exhaustive.

### Abstracts titles referenced:

#### 1. New Territories for ICIs & Navigating the Quest of Further Expansion

LBA2: POD1UM-303/InterAACT 2: Phase 3 Study of Retifanlimab (PD-1) With Carboplatin-Paclitaxel (C-P) in Patients (Pts) With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC) Not Previously Treated With Systemic Chemotherapy (Chemo)

LBA5: A randomized phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)

LBA4: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study

7090: Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

#### 2. Charting the Course for Radioligand Therapy in Prostate Cancer

LBA1: A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3

LBA65: Efficacy of <sup>177</sup>Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)

LBA66: UpFrontPSMA : A Randomised Phase 2 Study of Sequential <sup>177</sup>Lu-PSMA-617 and Docetaxel (D) versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

#### 3. Peering Ahead: The Next Wave of ADCs in View

19590: BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (UC)

754P: Initial results from a first-in-human study of AZD5335, a folate receptor  $\alpha$  (FR $\alpha$ )-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC)

6070: Interim Results of a Phase 1 Study of SGN-PDL1V (PF-08046054) in Patients with PDL1-Expressing Solid Tumors – PD-1 directed ADC



**Contact our team to discuss  
your oncology research needs.**



**Lindsay Widger**  
Research Director

[l.widger@beyondblueinsight.com](mailto:l.widger@beyondblueinsight.com)



**Paula Coyle**

Research Director

[p.coyle@beyondblueinsight.com](mailto:p.coyle@beyondblueinsight.com)



**Siobhan Davies**

Research Consultant

[s.davies@beyondblueinsight.com](mailto:s.davies@beyondblueinsight.com)